Para chegar a este momento muitas foram as Pessoas que me apoiaram e incentivaram a continuar nos momentos de dúvidas e anseios.
Ao meu orientador Professor Arsénio Fialho pela oportunidade que me concedeu ao permitir a minha integração na sua equipa, assim como toda a disponibilidade demonstrada para me ajudar e orientar;
Ao Professor Melo Cristino pelo acompanhamento do processo de co-orientação deste projeto;
À Dalila Mil-Homens pela sua permanente prontidão para me auxiliar e pelos inúmeros conhecimentos que me foi transmitindo ao logo do projeto, pois sem a sua amizade, ajuda e força não teria sido possível a realização deste trabalho;
A todos os colegas do BSRG que sempre se prontificaram para me auxiliar e em especial ao Nuno Bernardes, à Bruna Mota, à Teresa Estevens, à Fátima Gil e à Sofia Ferreira;
À minha família pelo apoio que me deu, em especial ao meu Filho que sempre me acompanhou nas idas ao laboratório fora de horas e aos fins de semana e à minha irmã pela força que me transmitiu;
1. Stock TWGaJB. The Histidine Protein Kinase Superfamily. Advances in Microbial Physiology. 1999;41:139-227.
2. Mil-Homens D. Burkholderia cenocepacia pathogenesis: unraveling the virulence functions of trimeric autotransporter adhesins and development of alternative therapies to target this pathogen. PhD thesis. 2012;IST.
3. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008;9.
4. Roy A. KA, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature Protocols. 2010;5:725-38.
5. Burkholder WH. Sour skin, a bacterial rot of onion bulbs. Phytopathology 1950;40:115-7.
6. Yabuuchi E KY, Oyaizu H, Yano I, Hotta H, Hashimoto Y, Ezaki T, Arakawa M. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol. 1992;36 (12):1251-75.
7. Coenye T, Mahenthiralingam E, Henry D, LiPuma JJ, Laevens S, Gillis M, et al. Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. International Journal of Systematic and Evolutionary Microbiology. 2001 July 1, 2001;51(4):1481-90.
8. Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, Coopman R, et al. Occurrence of Multiple Genomovars of Burkholderia cepacia in Cystic Fibrosis Patients and Proposal of Burkholderia multivorans sp. nov. International Journal of Systematic Bacteriology. 1997 October 1, 1997;47(4):1188-200.
9. Coenye T, Vandamme P, LiPuma JJ, Govan JRW, Mahenthiralingam E. Updated Version of the Burkholderia cepacia Complex Experimental Strain Panel. Journal of Clinical Microbiology. 2003 June 1, 2003;41(6):2797-8.
10. O'Sullivan LA, Mahenthiralingam E. Biotechnological potential within the genus Burkholderia. Letters in Applied Microbiology. 2005;41(1):8-11.
11. Leitão J, Sousa S, Ferreira A, Ramos C, Silva I, Moreira L. Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepaciat complex pathogens and related species. Applied Microbiology and Biotechnology. 2010;87(1):31-40.
12. Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Micro. 2005;3(2):144-56.
13. Vandamme P, Holmes B, Coenye T, Goris J, Mahenthiralingam E, LiPuma JJ, et al. Burkholderia cenocepacia sp. nov. a new twist to an old story. Research in Microbiology. 2003;154(2):91-6.
14. Vermis K, Coenye T, LiPuma JJ, Mahenthiralingam E, Nelis HJ, Vandamme P. Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. International Journal of Systematic and Evolutionary Microbiology. 2004 May 1, 2004;54(3):689-91.
15. LiPuma JJ. The Changing Microbial Epidemiology in Cystic Fibrosis. Clinical Microbiology Reviews. 2010 April 2010;23(2):299-323.
16. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiological Reviews. 1996 September 1, 1996;60(3):539-74.
17. Mil-Homens D, Rocha EPC, Fialho AM. Genome-wide analysis of DNA repeats in Burkholderia cenocepacia J2315 identifies a novel adhesin-like gene unique to epidemic-associated strains of the ET-12 lineage. Microbiology. 2010 April 1, 2010;156(4):1084-96.
18. Mann T, Ben-David D, Zlotkin A, Shachar D, Keller N, Toren A, et al. An outbreak of Burkholderia cenocepacia; bacteremia in immunocompromised oncology patients. Infection. 2010;38(3):187-94.
19. Lipuma J, Spilker T, GILL L, CAMPBELL P, LIU L, MAHENTHIRALINGAM E. Disproportionate Distribution of Burkholderia cepacia Complex Species and Transmissibility Markers in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2001 July 1, 2001;164(1):92-6.
20. Johnston RB. Clinical aspects of chronic granulomatous disease Current Opinion in Hematology 2001;8(1):17-22.
21. Foundation CF. Cystic Fibrosis Foundation. http://wwwcfforg. 2012, June 2012.
22. Collins F. Cystic fibrosis: molecular biology and therapeutic implications. Science. 1992 May 8, 1992;256(5058):774-9.
23. Loureiro P, Pacheco, P., Duarte, A., Albuquerque, C. & Lavinha, J. . Geografia genética e prevenção da fibrose quística em Portugal. Arquivos do Instituto Nacional de saúde 1994;20-21:35-41.
24. Kerem B RJ, Buchanam JA,, Markiewicz D CT, Chairavart A,, Buchwald M TL. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073-80.
25. Welsh MJS, A. E. . Molecular mechanisms of CFTR chloride channel dysfunction in cystic-fibrosis. Cell. 1993;73:1251-4.
26. Coutinho CP, dos Santos SC, Madeira A, Mira NP, Moreira AS, Sá-Correia I. Long-term colonization of the cystic fibrosis lung by Burkholderia cepacia complex bacteria: epidemiology, clonal variation and genome-wide expression alterations. Frontiers in Cellular and Infection Microbiology. 2011 2011-December-2;1.
27. Mahenthiralingam E, Baldwin A, Dowson CG. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. Journal of Applied Microbiology. 2008;104(6):1539-51.
28. Johnson W.M. TSD, Rozee K. R. Linkage Analysis of Geographic and Clinical Clusters in Pseudomonas cepacia Infections by Multilocus Enzyme Electrophoresis and Ribotyping journal of clinical microbiology. 1994;32:924-30.
29. LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil. The Lancet. 2002;359(9322):2002-3.
30. Loutet SA, Valvano MA. Extreme antimicrobial peptide and polymyxin B resistance in the genus Burkholderia. Frontiers in Cellular and Infection Microbiology. 2011 2011-July-22;1.
31. Chung JW, Speert DP. Proteomic identification and characterization of bacterial factors associated with Burkholderia cenocepacia survival in a murine host. Microbiology. 2007 January 1, 2007;153(1):206-14.
32. Sajjan U, Wu, Yijun,Kent, Geraldine, Forstner, Janet. Preferential adherence of cable-piliated Burkholderia cepacia to respiratory epithelia of CF knockout mice and human cystic fibrosis lung explants. Journal of Medical Microbiology. 2000 October 1, 2000;49(10):875-85.
33. Forstner USSaJF. Role of a 22-kilodalton pilin protein in binding of Pseudomonas cepacia to buccal epithelial cells. Infect Immun. 1993 61((8)):3157-63. 34. Eaves-Pyles T, Murthy K, Liaudet L, Virág L, Ross G, Soriano FG, et al. Flagellin, a Novel Mediator of Salmonella-Induced Epithelial Activation and Systemic Inflammation: IκBα Degradation, Induction of Nitric Oxide Synthase, Induction of
Proinflammatory Mediators, and Cardiovascular Dysfunction. The Journal of Immunology. 2001 January 15, 2001;166(2):1248-60.
35. Lyczak JB, Cannon CL, Pier GB. Lung Infections Associated with Cystic Fibrosis. Clinical Microbiology Reviews. 2002 April 1, 2002;15(2):194-222.
36. Urban TA, Griffith A, Torok AM, Smolkin ME, Burns JL, Goldberg JB. Contribution of Burkholderia cenocepacia Flagella to Infectivity and Inflammation. Infection and Immunity. 2004 September 1, 2004;72(9):5126-34.
37. Albrecht M, Wang W, Shamova O, Lehrer R, Schiller N. Binding of protegrin-1 to Pseudomonas aeruginosa and Burkholderia cepacia. Respiratory Research. 2002;3(1):18.
38. Nelson JW, Butler SL, Brown PH, Greening AP, Govan JRW. Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. Journal of Medical Microbiology. 1993 July 1, 1993;39(1):39-47.
39. Hughes JE, Stewart J, Barclay GR, Govan JR. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia. Infection and Immunity. 1997 October 1, 1997;65(10):4281-7.
40. Cunha MV, Sousa SA, Leitão JH, Moreira LM, Videira PA, Sá-Correia I. Studies on the Involvement of the Exopolysaccharide Produced by Cystic Fibrosis-
Associated Isolates of the Burkholderia cepacia Complex in Biofilm Formation and in Persistence of Respiratory Infections. Journal of Clinical Microbiology. 2004 July 1, 2004;42(7):3052-8.
41. Herasimenka Y MB, Maura Mattiuzzo, Paola Cescutti, Renato Gennaro, Roberto Rizzo Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens. Peptides. 2005;26:1127-32.
42. Zlosnik JEA, Hird TJ, Fraenkel MC, Moreira LM, Henry DA, Speert DP. Differential Mucoid Exopolysaccharide Production by Members of the Burkholderia cepacia Complex. Journal of Clinical Microbiology. 2008 April 2008;46(4):1470-3. 43. Cescutti P, Impallomeni G, Garozzo D, Sturiale L, Herasimenka Y, Lagatolla C, et al. Exopolysaccharides produced by a clinical strain of Burkholderia cepacia isolated from a cystic fibrosis patient. Carbohydrate Research. 2003;338(23):2687- 95.
44. Conway B-AD, Chu KK, Bylund J, Altman E, Speert DP. Production of Exopolysaccharide by Burkholderia cenocepacia Results in Altered Cell-Surface Interactions and Altered Bacterial Clearance in Mice. Journal of Infectious Diseases. 2004 September 1, 2004;190(5):957-66.
45. Sousa SA, Ulrich M, Bragonzi A, Burke M, Worlitzsch D, Leitão JH, et al. Virulence of Burkholderia cepacia complex strains in gp91phox−/− mice. Cellular Microbiology. 2007;9(12):2817-25.
46. Bylund J, Burgess L-A, Cescutti P, Ernst RK, Speert DP. Exopolysaccharides from Burkholderia cenocepacia Inhibit Neutrophil Chemotaxis and Scavenge Reactive Oxygen Species. Journal of Biological Chemistry. 2006 February 3, 2006;281(5):2526-32.
47. Loutet SA, Valvano MA. A Decade of Burkholderia cenocepacia Virulence Determinant Research. Infection and Immunity. 2010 October 2010;78(10):4088-100. 48. Lazdunski AM, Ventre I, Sturgis JN. Regulatory circuits and communication in Gram-negative bacteria. Nat Rev Micro. 2004;2(7):581-92.
49. Venturi V, Friscina A, Bertani I, Devescovi G, Aguilar C. Quorum sensing in the Burkholderia cepacia complex. Research in Microbiology. 2004;155(4):238-44. 50. Riedel K, Hentzer M, Geisenberger O, Huber B, Steidle A, Wu H, et al. N- Acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology. 2001 December 1, 2001;147(12):3249-62.
51. McCarthy Y, Yang L, Twomey KB, Sass A, Tolker-Nielsen T, Mahenthiralingam E, et al. A sensor kinase recognizing the cell–cell signal BDSF
(cis-2-dodecenoic acid) regulates virulence in Burkholderia cenocepacia. Molecular Microbiology. 2010;77(5):1220-36.
52. Brackman G, Hillaert U, Van Calenbergh S, Nelis HJ, Coenye T. Use of quorum sensing inhibitors to interfere with biofilm formation and development in Burkholderia multivorans and Burkholderia cenocepacia. Research in Microbiology. 2009;160(2):144-51.
53. Rasmussen TB, Bjarnsholt T, Skindersoe ME, Hentzer M, Kristoffersen P, Köte M, et al. Screening for Quorum-Sensing Inhibitors (QSI) by Use of a Novel Genetic System, the QSI Selector. Journal of Bacteriology. 2005a March 1, 2005;187(5):1799-814.
54. Rasmussen TB, Skindersoe ME, Bjarnsholt T, Phipps RK, Christensen KB, Jensen PO, et al. Identity and effects of quorum-sensing inhibitors produced by Penicillium species. Microbiology. 2005b May 1, 2005;151(5):1325-40.
55. Rasmussen TB, Givskov M. Quorum-sensing inhibitors as anti-pathogenic drugs. International Journal of Medical Microbiology. 2006;296(2–3):149-61.
56. Dunne WM. Bacterial Adhesion: Seen Any Good Biofilms Lately? Clinical Microbiology Reviews. 2002 April 1, 2002;15(2):155-66.
57. Tomlin KL, Malott RJ, Ramage G, Storey DG, Sokol PA, Ceri H. Quorum- Sensing Mutations Affect Attachment and Stability of Burkholderia cenocepacia Biofilms. Applied and Environmental Microbiology. 2005 September 2005;71(9):5208-18.
58. Huber B, Riedel K, Köthe M, Givskov M, Molin S, Eberl L. Genetic analysis of functions involved in the late stages of biofilm development in Burkholderia cepacia H111. Molecular Microbiology. 2002;46(2):411-26.
59. Pan J, Ren D. Quorum sensing inhibitors: a patent overview. Expert Opinion on Therapeutic Patents. 2009;19(11):1581-601.
60. Kooi C, Subsin B, Chen R, Pohorelic B, Sokol PA. Burkholderia cenocepacia ZmpB Is a Broad-Specificity Zinc Metalloprotease Involved in Virulence. Infection and Immunity. 2006 July 2006;74(7):4083-93.
61. Kooi C, Corbett C. R., Sokol P. A. Functional Analysis of the Burkholderia cenocepacia ZmpA Metalloprotease. J Bacteriol. 2005;187 (13):4421-9.
62. Corbett CR, Burtnick MN, Kooi C, Woods DE, Sokol PA. An extracellular zinc metalloprotease gene of Burkholderia cepacia. Microbiology. 2003 August 1, 2003;149(8):2263-71.
63. Miethke M, Marahiel MA. Siderophore-Based Iron Acquisition and Pathogen Control. Microbiology and Molecular Biology Reviews. 2007 September 2007;71(3):413-51.
64. Whitby PW, VanWagoner TM, Springer JM, Morton DJ, Seale TW, Stull TL. Burkholderia cenocepacia utilizes ferritin as an iron source. Journal of Medical Microbiology. 2006 June 1, 2006;55(6):661-8.
65. Darling P. CM, Cox A.D., Sokol A. P. Siderophore Production by Cystic Fibrosis Isolates of Burkholderia cepacia. Infect Immun. 1998;66:874–7.
66. Uehlinger S, Schwager S, Bernier SP, Riedel K, Nguyen DT, Sokol PA, et al. Identification of Specific and Universal Virulence Factors in Burkholderia cenocepacia Strains by Using Multiple Infection Hosts. Infection and Immunity. 2009 September 2009;77(9):4102-10.
67. Mullen T, Markey K, Murphy P, McClean S, Callaghan M. Role of lipase in Burkholderia cepacia complex (Bcc) invasion of lung epithelial cells. European Journal of Clinical Microbiology & Infectious Diseases. 2007;26(12):869-77.
68. Gerlach RG, Hensel M. Protein secretion systems and adhesins: The molecular armory of Gram-negative pathogens. International Journal of Medical Microbiology. 2007;297(6):401-15.
69. Berg G, Eberl L, Hartmann A. The rhizosphere as a reservoir for opportunistic human pathogenic bacteria. Environmental Microbiology. 2005;7(11):1673-85.
70. Leitão J, Sousa S, Cunha M, Salgado M, Melo-Cristino J, Barreto M, et al. Variation of the antimicrobial susceptibility profiles of & Burkholderia cepacia; complex clonal isolates obtained from chronically infected cystic fibrosis patients: a
five-year survey in the major Portuguese treatment center. European Journal of Clinical Microbiology & Infectious Diseases. 2008;27(11):1101-11.
71. W Beckman TGL. Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source. J Bacteriol. 1979;140(3):1126-8.
72. Yuan Fang, Miao-miao Lou, Bin Li, Guan-Lin Xie, Fang Wang, Li-Xin Zhang, et al. Characterization of Burkholderia cepacia complex from cystic fibrosis patients in China and their chitosan susceptibility. World Journal of Microbiology and Biotechnology 2010;26(3):443-50.
73. Fux CA CJ, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol. 2005;13(1):34-40.
74. Moore R A HRE. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother. 1986 30: 923–6.
75. Aronoff SC. Outer membrane permeability in Pseudomonas cepacia: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. Antimicrob Agents Chemother. 1988; 32(11):1636–9.
76. Rajyaguru JM, Muszynski MJ. Association of resistance to trimethoprim/sulphamethoxazole, chloramphenicol and quinolones with changes in major outer membrane proteins and lipopolysaccharide in Burkholderia cepacia. Journal of Antimicrobial Chemotherapy. 1997 December 1, 1997;40(6):803-9.
77. Sass A, Marchbank A, Tullis E, LiPuma J, Mahenthiralingam E. Spontaneous and evolutionary changes in the antibiotic resistance of Burkholderia cenocepacia observed by global gene expression analysis. BMC Genomics. 2011;12(1):373.
78. Aaron S, Ferris W, Henry D, Speert D, MacDonald N. Multiple Combination Bactericidal Antibiotic Testing for Patients with Cystic Fibrosis Infected with Burkholderia cepacia. American Journal of Respiratory and Critical Care Medicine. 2000 April 1, 2000;161(4):1206-12.
79. Fialho AM, Mil-Homens D. Trimeric autotransporter adhesins in members of the Burkholderia cepacia complex: a multifunctional family of proteins implicated in virulence. Frontiers in Cellular and Infection Microbiology. 2011 2011-December-7;1. 80. Linke D, Riess T, Autenrieth IB, Lupas A, Kempf VAJ. Trimeric autotransporter adhesins: variable structure, common function. Trends in Microbiology. 2006;14(6):264-70.
81. Serruto D, Spadafina T, Scarselli M, Bambini S, Comanducci M, Höhle S, et al. HadA is an atypical new multifunctional trimeric coiled-coil adhesin of Haemophilus influenzae biogroup aegyptius, which promotes entry into host cells. Cellular Microbiology. 2009;11(7):1044-63.
82. Heise T, Dersch P. Identification of a domain in Yersinia virulence factor YadA that is crucial for extracellular matrix-specific cell adhesion and uptake. Proceedings of the National Academy of Sciences of the United States of America. 2006 February 28, 2006;103(9):3375-80.
83. Hoiczyk E, Roggenkamp A, Reichenbecher M, Lupas A, Heesemann J. Structure and sequence analysis of Yersinia YadA and Moraxella UspAs reveal a novel class of adhesins. EMBO J. 2000;19(22):5989-99.
84. Nummelin H, Merckel MC, Leo JC, Lankinen H, Skurnik M, Goldman A. The Yersinia adhesin YadA collagen-binding domain structure is a novel left-handed parallel [beta]-roll. 2004;23(4):701-11.
85. Meng G, Surana NK, St Geme JW, Waksman G. Structure of the outer membrane translocator domain of the Haemophilus influenzae Hia trimeric autotransporter. EMBO J. 2006;25(11):2297-304.
86. Capecchi B, Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V, Taddei A, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Molecular Microbiology. 2005;55(3):687-98.
87. Raghunathan D, Wells TJ, Morris FC, Shaw RK, Bobat S, Peters SE, et al. SadA, a Trimeric Autotransporter from Salmonella enterica Serovar Typhimurium, Can Promote Biofilm Formation and Provides Limited Protection against Infection. Infection and Immunity. 2011 November 1, 2011;79(11):4342-52.
88. Jones AM, Boucher PE, Williams CL, Stibitz S, Cotter PA. Role of BvgA phosphorylation and DNA binding affinity in control of Bvg-mediated phenotypic phase transition in Bordetella pertussis. Molecular Microbiology. 2005;58(3):700-13. 89. Krell TJL, Busch A, Silva-Jiménez H, Guazzaroni ME, Ramos JL. Bacterial Sensor Kinases: Diversity in the Recognition of Environmental Signals. Annual Review of Microbiology. 2010;64:539-59.
90. Krell T, Lacal J, Busch A, Silva-Jiménez H, Guazzaroni M-E, Ramos JL. Bacterial Sensor Kinases: Diversity in the Recognition of Environmental Signals. Annual Review of Microbiology. 2010;64(1):539-59.
91. Cock PJA, Whitworth DE. Evolution of Prokaryotic Two-Component System Signaling Pathways: Gene Fusions and Fissions. Molecular Biology and Evolution. 2007 November 1, 2007;24(11):2355-7.
92. Alex LA, Simon MI. Protein histidine kinases and signal tranduction in prokaryotes and eukaryotes. Trends in Genetics. 1994;10(4):133-8.
93. Gao R, Stock AM. Biological Insights from Structures of Two-Component Proteins. Annual Review of Microbiology. 2009;63(1):133-54.
94. Skerker JM, Laub MT. Cell-cycle progression and the generation of asymmetry in Caulobacter crescentus. Nat Rev Micro. 2004;2(4):325-37.
95. Caimano MJ, Kenedy MR, Kairu T, Desrosiers DC, Harman M, Dunham-Ems S, et al. The Hybrid Histidine Kinase Hk1 Is Part of a Two-Component System That Is Essential for Survival of Borrelia burgdorferi in Feeding Ixodes scapularis Ticks. Infection and Immunity. 2011 August 1, 2011;79(8):3117-30.
96. Parkinson JS, Kofoid EC. Communication Modules in Bacterial Signaling Proteins. Annual Review of Genetics. 1992;26(1):71-112.
97. Appleman JA, Chen L-L, Stewart V. Probing Conservation of HAMP Linker Structure and Signal Transduction Mechanism through Analysis of Hybrid Sensor Kinases. Journal of Bacteriology. 2003 August 15, 2003;185(16):4872-82.
98. Williams SB, Stewart V. MicroReview: Functional similarities among two- component sensors and methyl-accepting chemotaxis proteins suggest a role for linker region amphipathic helices in transmembrane signal transduction. Molecular Microbiology. 1999;33(6):1093-102.
99. Mascher T, Helmann JD, Unden G. Stimulus Perception in Bacterial Signal- Transducing Histidine Kinases. Microbiology and Molecular Biology Reviews. 2006 December 2006;70(4):910-38.
100. Bruscia E SF, Sinibaldi P, Goncz K, Novelli G, Gruenert DC. Isolation of CF cell lines corrected at F508-CFTR locus by SFHR-mediated targeting Gene Ther. 2002;9(11):683-5.
101. Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. American Journal of Respiratory Cell and Molecular Biology. 1994 January 1, 1994;10(1):38-47.
102. Seed KD, Dennis JJ. Development of Galleria mellonella as an Alternative Infection Model for the Burkholderia cepacia Complex. Infection and Immunity. 2008 March 2008;76(3):1267-75.
103. Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax. 2002 February 1, 2002;57(2):142-5.
104. Baldwin A, Sokol PA, Parkhill J, Mahenthiralingam E. The Burkholderia cepacia Epidemic Strain Marker Is Part of a Novel Genomic Island Encoding Both Virulence and Metabolism-Associated Genes in Burkholderia cenocepacia. Infection and Immunity. 2004 March 1, 2004;72(3):1537-47.
105. Mil-Homens D, Bernardes N, Fialho AM. The antibacterial properties of docosahexaenoic omega-3 fatty acid against the cystic fibrosis multiresistant pathogen Burkholderia cenocepacia. FEMS Microbiology Letters. 2012;328(1):61-9. 106. Mil-Homens D, Fialho AM. A BCAM0223 Mutant of Burkholderia cenocepacia Is Deficient in Hemagglutination, Serum Resistance, Adhesion to Epithelial Cells and Virulence. PLoS ONE. 2012;7(7):e41747.
107. Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods. 2001;25(4):402-8.
108. Attia AS, Lafontaine ER, Latimer JL, Aebi C, Syrogiannopoulos GA, Hansen EJ. The UspA2 Protein of Moraxella catarrhalis Is Directly Involved in the Expression of Serum Resistance. Infection and Immunity. 2005 April 1, 2005;73(4):2400-10. 109. Holden MTG, Seth-Smith HMB, Crossman LC, Sebaihia M, Bentley SD, Cerdeño-Tárraga AM, et al. The Genome of Burkholderia cenocepacia J2315, an Epidemic Pathogen of Cystic Fibrosis Patients. Journal of Bacteriology. 2009 January 1, 2009;191(1):261-77.
110. Zhang Z. SS, Wagner L., Miller W. A greedy algorithm for aligning DNA sequences. J Comput Biol 2000. 2000;7(1-2):203-14.
111. Ryan RP, McCarthy Y, Watt SA, Niehaus K, Dow JM. Intraspecies Signaling Involving the Diffusible Signal Factor BDSF (cis-2-Dodecenoic Acid) Influences Virulence in Burkholderia cenocepacia. Journal of Bacteriology. 2009 August 1, 2009;191(15):5013-9.
112. Kapperud G NE, Skurnik M, Nesbakken T. Plasmid-mediated surface fibrillae of Yersinia pseudotuberculosis and Yersinia enterocolitica: relationship to the outer membrane protein YOP1 and possible importance for pathogenesis. Infect Immun. 1987 55(9):2247-54.
113. Pearson MM, Lafontaine ER, Wagner NJ, St. Geme JW, Hansen EJ. A hag Mutant of Moraxella catarrhalis Strain O35E Is Deficient in Hemagglutination, Autoagglutination, and Immunoglobulin D-Binding Activities. Infection and Immunity. 2002 August 1, 2002;70(8):4523-33.
114. Aricò B, Nuti S, Scarlato V, Rappuoli R. Adhesion of Bordetella pertussis to eukaryotic cells requires a time-dependent export and maturation of filamentous hemagglutinin. Proceedings of the National Academy of Sciences. 1993 October 1, 1993;90(19):9204-8.
115. Baldwin A, Mahenthiralingam E, Drevinek P, Pope C, Waine DJ, Henry DA, et al. Elucidating Global Epidemiology of Burkholderia multivorans in Cases of Cystic Fibrosis by Multilocus Sequence Typing. Journal of Clinical Microbiology. 2008 January 2008;46(1):290-5.
116. Frangolias DD, Mahenthiralingam E, Rae S, Raboud JM, Davidson AGF, Wittmann R, et al. Burkholderia cepacia in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 1999 November 1, 1999;160(5):1572-7. 117. Baird RM, Brown H, Smith AW, Watson ML. Burkholderia cepacia is resistant to the antimicrobial activity of airway epithelial cells. Immunopharmacology. 1999;44(3):267-72.
118. Cassidy CM, Donnelly RF, Elborn JS, Magee ND, Tunney MM. Photodynamic Antimicrobial Chemotherapy (PACT) in combination with antibiotics for treatment of Burkholderia cepacia complex infection. Journal of Photochemistry and Photobiology B: Biology. 2012;106(0):95-100.
119. Gilmour R, Foster JE, Sheng Q, McClain JR, Riley A, Sun P-M, et al. New Class of Competitive Inhibitor of Bacterial Histidine Kinases. Journal of Bacteriology. 2005 December 1, 2005;187(23):8196-200.